AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00671255 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ramelteon placebo-matching, tablets, orally, each night for up to 35 consecutive days.
Study NCT00722150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: 2 mg/kg/day x 7 days
Study NCT00722150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artesunate
Description: 4 mg/kg/day x 7 days
Study NCT00722150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate
Description: 6 mg/kg/day x 7 days
Study NCT00935558 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DC vaccine
Description: DC vaccination regime consist of primary 10 intradermal injections of 1-2 weeks interval. At the time of each vaccine 6 MIU/m² IL-2 will be administered sc. Zadaxin 1.6 mg is injected sc twice a week. and tablet Aromatase inhibitor is administered ; Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
Study NCT00935558 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DC vaccine
Description: DC vaccination regime consist of primary 10 intradermal injections of 1-2 weeks interval. At the time of each vaccine 6 MIU/m² IL-2 will be administered sc. Zadaxin 1.6 mg is injected sc twice a week. and tablet Aromatase inhibitor is administered ; Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
Study NCT00935558 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aromatase inhibitor
Description: Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
Study NCT02579655 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Copayment Elimination
Description: Patients will receive preventive medications for their chronic conditions free of charge (without the 30% copayment seniors normally pay for their medications)
Study NCT02579655 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Personalized Education
Description: Tailored Education focusing on optimizing use and adherence to guideline recommended medications, as well as appropriate lifestyle
Study NCT01819909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative Jackins Exercise Protocol
Description: Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
Study NCT01819909 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Postoperative Pulleys Exercise Protocol
Description: Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
Study NCT00903929 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eltrombopag
Description: dose escalation
Study NCT03406065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate supplementation
Description: The experimental procedure for each athlete included a 10-day NaHCO3 supplementation in a progressive-dose regimen in order to reduce the likelihood of gastrointestinal side effects (from 25 to 100 mg ∙ kg-1). NaHCO3 was administered in the form of unmarked disk-shaped tablets (Alkala T, SANUM, Poland). The tablets were ingested with at least 250 mL of water and could be either swallowed or dissolved in the mouth. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
Study NCT03406065 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: The experimental procedure for each athlete included a 10-day placebo administration. Placebo was ingested with at least 250 mL of water. On training days the supplements were taken in the morning, in the evening and 1.5 hours before training session. On rest days the supplements were taken in the morning, in the afternoon and in the evening.
Study NCT01109030 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone+Citalopram+Chlordiazepoxide
Description: Pioglitazone 15 mg every 12 hours for six weeks Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks
Study NCT01109030 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo+ Citalopram+ Chlordiazepoxide
Description: Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks
Study NCT01913483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bivalirudin
Description: Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
Study NCT01913483 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Unfractionated Heparin
Description: Unfractionated heparin is an anticoagulant.
Study NCT02302963 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AP System (DiAs or inControl) with USS Virginia
Description: Subject will participate in two 24-hour study insulin pump and AP System training sessions. At the conclusion of each training session, subject will wear the equipment at home for a total of 5 weeks.
Study NCT02302963 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sensor-Augmented Pump Therapy (placebo)
Description: Subject will participate in 5 weeks use of CGM and personal insulin pump at home.
Study NCT03405948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intra muscular injection of Botulinum toxin
Description: posture and gait analysis were performed before injection and 4 to 6 weeks after injection
Study NCT03405948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra muscular injection of Botulinum toxin
Description: posture and gait analysis were performed before injection and 4 to 6 weeks after injection
Study NCT02173795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® Respimat®
Study NCT02173795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berodual® MA HFA
Study NCT02916420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: 4mg/day, d1-d21, 28 days per cycle
Study NCT02916420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: ≤70 years,40mg/day; >70 years,20mg/day, d1、d8、d15、d22, 28 days per cycle
Study NCT01047657 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low caloric diet plus orlistat and sibutramine
Description: All subjetcs
Study NCT00630305 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: alphafilcon A toric
Description: Subjects that were randomized to receive alphafilcon A toric during one of the four sessions (Sessions A, B, C and D).
Study NCT00630305 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: lotrafilcon B toric
Description: Subjects that were randomized to receive lotrafilcon B toric during one of the four sessions (Sessions A, B, C and D).
Study NCT00630305 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: senofilcon A toric
Description: Subjects that were randomized to receive senofilcon A toric during one of the four sessions (Sessions A, B, C and D).
Study NCT00464178 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Bortezomib will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
Study NCT03594890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVX836 (Intramuscular)
Description: 2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
Study NCT03594890 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Intramuscular)
Description: 2 consecutive administrations of placebo at Day 1 and Day 29.
Study NCT03594890 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OVX836 (Intranasal)
Description: 2 consecutive administrations of OVX836 vaccine at Day 1 and Day 29.
Study NCT03594890 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Intranasal)
Description: 2 consecutive administrations of placebo at Day 1 and Day 29.
Study NCT01634438 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractionated heparin
Description: unfractionated heparin
Study NCT01634438 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: unfractionated heparin
Description: unfractionated heparin
Study NCT01920711 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 50mg, 100mg and 200 mg dosage strengths will be available for dose adjustments.
Study NCT01920711 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan
Description: Valsartan 40mg, 80mg and 160mg dosage strengths will be available for dose adjustments.
Study NCT01162330 — intervention group
Intervention type: OTHER
Intervention: Screening urine and saliva tests for congenital Cytomegalovirus
Description: With consent for the study babies who are referred for further hearing tests will have a urine and saliva sample sent to be analysed for CMV infection
Study NCT02838407 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: BAL fluid sampling
Description: Following routine BAL procedures at the hospital, collection of BAL fluid samples: at least 2 mL, at Day 0.
Study NCT02838407 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Nasopharyngeal swab sampling
Description: 1 swab, Day 0
Study NCT04492280 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: After approval of the ethical committee of faculty of Medicine Ain Shams University and obtaining a written informed consent from all patients or their legal guardians, the study will be conducted on 66 patients subdivided randomly via computer closed envelopes method into 3 equal groups, 22 patients for each group; group HF (hydrocortisone \& fludrocortisone), group H (hydrocortisone) and group C (control group).
Study NCT04492280 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Hydrocortisone
Description: After approval of the ethical committee of faculty of Medicine Ain Shams University and obtaining a written informed consent from all patients or their legal guardians, the study will be conducted on 66 patients subdivided randomly via computer closed envelopes method into 3 equal groups, 22 patients for each group; group HF (hydrocortisone \& fludrocortisone), group H (hydrocortisone) and group C (control group).
Study NCT00511355 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2
Description: Nomegestrol Acetate and Estradiol (NOMAC-E2) Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
Study NCT00511355 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levonorgestrel and Ethinyl Estradiol
Description: Levonorgestrel and Ethinyl Estradiol (LNG-EE) Tablets, 150 mcg LNG and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
Study NCT01889979 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: 100 mg of Tramadol was applied in the forearm SC (single dose).
Study NCT01889979 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 ml of a sterile solution was applied in the forearm SC (single dose).
Study NCT03803644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: Part 1 dose escalation
Study NCT03803644 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: CC-92480
Study NCT04067063 — intervention group
Intervention type: OTHER
Intervention: Self-administered evaluation questionnaire
Description: Smartphone app with MeMind questionnaires
Study NCT03601286 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lentiviral vector transduced CD34+ cells
Description: Gene therapy for X-linked Severe Combined Immunodeficiency will be performed by introduction a normal copy of the IL2RG gene into the blood forming stem cells (CD34+ cells) of the patient's bone marrow by using a type of gene delivery system (in this trial called a lentiviral vector). The gene corrected cells are then transplanted back into the patient.
Study NCT02758158 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tri-modal imaging
Description: This trimodal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified.
Study NCT02237287 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: wound dressing with VAC and sNAG without antiaggregation
Study NCT02237287 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: wound dressing with VAC and sNAG without antiaggregation
Study NCT02237287 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: wound dressing with VAC
Study NCT02237287 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: wound dressing with VAC
Study NCT02237287 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: wound dressing with VAC
Study NCT02237287 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: wound dressing with VAC and sNAG under Antiaggregation
Study NCT00454805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2171
Description: Oral tablet
Study NCT00454805 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: intramuscular injection
Study NCT00454805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection
Study NCT03800875 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 27-hour inpatient intervention
Description: Subjects will be admitted at the research facility at 19:00. Each 27-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (22:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The infusion rate of either insulin alone or insulin and pramlintide will be changed manually based on the computer generated recommendation. The computer generated recommendations are based on a predictive algorithm.
Study NCT03800875 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 27-hour inpatient intervention
Description: Subjects will be admitted at the research facility at 19:00. Each 27-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (22:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The infusion rate of either insulin alone or insulin and pramlintide will be changed manually based on the computer generated recommendation. The computer generated recommendations are based on a predictive algorithm.
Study NCT01314300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Lidocaine 5% plaster
Study NCT02105415 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine / Propofol Admixture
Study NCT02105415 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etomidate
Study NCT00330473 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Insulin Inhalation Powder
Description: patient specific dose, inhaled, before meals, 9 months ( if patient chooses Human Insulin Inhalation Powder option)
Study NCT00330473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: patient specific dose, oral or injectable, before meals and/or as needed, 9 months. ( patients and investigator determine standard option therapy)
Study NCT01545700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control-saline
Description: Patients are randomized to receive saline 2 cc
Study NCT01545700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg
Description: Patients randomized to receive dexamethasone 4mg and 1 cc saline
Study NCT01545700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 8 mg
Description: Patients randomized to receive dexamethasone 8mg
Study NCT01545700 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control saline
Description: Patients are randomized to receive saline 2 cc
Study NCT01545700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 4 mg
Description: Patients are randomized to receive dexamethasone 4 mg and saline 1 cc
Study NCT01545700 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone 8 mg
Description: Patients are randomized to receive dexamethasone 8 mg
Study NCT04323904 — intervention group
Intervention type: OTHER
Intervention: Retrospective data collection
Description: Retrospective data collection from patients with hantavirus infection and matching control group patients.
Study NCT02228863 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Inmotion and Botox
Description: Concomitant use of Inmotion and Botox from the baseline
Study NCT02228863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Botox, then Inmotion
Description: At baseline Botox injection and 4 weeks after Inmotion
Study NCT02228863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Inmotion, then Botox
Description: Inmotion from the baseline, then Botox injection at 4 weeks after baseline
Study NCT02228863 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Late Inmotion and Botox
Description: No intervention until 4 weeks from the baseline. Then Inmotion and Botox injection
Study NCT04983160 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol
Description: Allopurinol
Study NCT04983160 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01831960 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cortexolone 17α-propionate
Study NCT00135122 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: prednisolone
Description: Prednisolone 60mg day 1 and 2 , 40mg day 3 and 4 , 20mg day 5 and 6
Study NCT02084277 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self-ligating brackets (SLB)
Study NCT02084277 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional brackets (CB)
Study NCT04377737 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: RT-PCR Covid-19
Description: estimation of the prevalence of positive rt-PCR in school children during the pandemic period
Study NCT00803179 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nutropin AQ
Description: Based on recommendations from the 2007 GH Deficiency Consensus Workshop on adult GH deficiency, the recommended initiation of treatment for adult males is 0.2mg/d and for women 0.4mg/d, with a titration upwards based on insulin-like growth factor (IGF-1) (product of GH stimulation at target tissues) levels and patient response. IGF-1 will be monitored at the 3,4,5 and 11 month intervals. For subjects under the age of 25 with an open epiphysis of the hand and/or wrist we will treat with the dose of 0.3mg/kg/week. Subjects will be on growth hormone for 8 months with a baseline visit prior to initiation of therapy and a 3 month follow-up visit after stopping therapy.
Study NCT03084640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: CMP-001 will be administered SC as per the dose and schedule specified in the respective arms.
Study NCT03084640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be administered as per the schedule specified in the respective arms.
Study NCT03084640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CMP-001
Description: CMP-001 will be administered IT as per the dose and schedule specified in the respective arms.
Study NCT03512145 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VIPUN Balloon Catheter
Description: Gastric motility is recorded continuously with the VIPUN Balloon Catheter for 10 hours.
Study NCT04132791 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo after awakening + aspirin before bedtime
Description: determine the difference in major adverse cardiovascular events between the group with aspirin after awakening and placebo before bedtime and the group with placebo after wakening and aspirin before bedtime.